BETAMIPRON

Details

Stereochemistry	ACHIRAL
Molecular Formula	C10H11NO3
Molecular Weight	193.1992
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)CCNC(=O)C1=CC=CC=C1

InChI

InChIKey=CWXYHOHYCJXYFQ-UHFFFAOYSA-N

InChI=1S/C10H11NO3/c12-9(13)6-7-11-10(14)8-4-2-1-3-5-8/h1-5H,6-7H2,(H,11,14)(H,12,13)

HIDE SMILES / InChI

Molecular Formula	C10H11NO3
Molecular Weight	193.1992
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/7861655
Curator's Comment: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/10211864 http://www.ncbi.nlm.nih.gov/pubmed/11426832 http://www.ncbi.nlm.nih.gov/pubmed/12023506

Betamipron (BP) is an amino acid derivative that has benzoyl and carboxyl groups in its structure, and it also has very low toxicity in mammals (LD50 in the rat, more than 3,000 mg/kg, i.v.). BP is a renal anionic transport inhibitor and decreases nephrotoxicity caused by high doses of carbapenems, anionic drugs, by inhibiting the drug accumulation in the renal cortex. BP significantly inhibited organic anion uptake by human organic anion transporter 1 (human-OAT1) and human-OAT3 in a dose-dependent manner. Panipenem-betamipron is marketed as Carbenin® (Sankyo Company, Tokyo, Japan).

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Solute carrier family 22 member 6 19 Target ID: Q4U2R8\|\|\|Q9NQC2 Gene ID: 9356.0 Gene Symbol: SLC22A6 Target Organism: Homo sapiens (Human) Sources: http://www.ncbi.nlm.nih.gov/pubmed/11426832	Inhibitor 8504		23.6 µM [Ki]
Solute carrier family 22 member 8 17 Target ID: Q8TCC7 Gene ID: 9376.0 Gene Symbol: SLC22A8 Target Organism: Homo sapiens (Human) Sources: http://www.ncbi.nlm.nih.gov/pubmed/11426832	Inhibitor 8504		48.3 µM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Bacterial infections 235 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1518122	Secondary		Approved 8583	Carbenin Approved Use Unknown Launch Date 1993

C_max

Value	Dose	Co-administered	Analyte	Population
7.25 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=40 \| https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_242/_article/-char/en	250 mg single, intravenous dose: 250 mg route of administration: Intravenous experiment type: SINGLE co-administered: PANIPENEM	PANIPENEM	BETAMIPRON plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
15.59 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=40 \| https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_242/_article/-char/en	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: PANIPENEM	PANIPENEM	BETAMIPRON plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
23.68 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=40 \| https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_242/_article/-char/en	1000 mg single, intravenous dose: 1000 mg route of administration: Intravenous experiment type: SINGLE co-administered: PANIPENEM	PANIPENEM	BETAMIPRON plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.47 μg/mL EXPERIMENT https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_242/_article/-char/en	125 mg single, intravenous dose: 125 mg route of administration: Intravenous experiment type: SINGLE co-administered: PANIPENEM	PANIPENEM	BETAMIPRON plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
14.1 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=40 \| https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_265/_article/-char/en	500 mg 2 times / day multiple, intravenous dose: 500 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: PANIPENEM	PANIPENEM	BETAMIPRON plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
16.19 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=40 \| https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_265/_article/-char/en	500 mg 2 times / day multiple, intravenous dose: 500 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: PANIPENEM	PANIPENEM	BETAMIPRON plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
33.23 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=40 \| https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_265/_article/-char/en	1000 mg 2 times / day multiple, intravenous dose: 1000 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: PANIPENEM	PANIPENEM	BETAMIPRON plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
25.69 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=40 \| https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=51 \| https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_265/_article/-char/en	1000 mg 2 times / day multiple, intravenous dose: 1000 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: PANIPENEM	PANIPENEM	BETAMIPRON plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
18.33 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=41 \| https://www.jstage.jst.go.jp/article/antibiotics1968b/45/2/45_208/_article/-char/en	10 mg/kg single, intravenous dose: 10 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: PANIPENEM	PANIPENEM	BETAMIPRON plasma	Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN
38.74 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=41 \| https://www.jstage.jst.go.jp/article/antibiotics1968b/45/2/45_208/_article/-char/en	20 mg/kg single, intravenous dose: 20 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: PANIPENEM	PANIPENEM	BETAMIPRON plasma	Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN
50.08 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=41 \| https://www.jstage.jst.go.jp/article/antibiotics1968b/45/2/45_208/_article/-char/en	30 mg/kg single, intravenous dose: 30 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: PANIPENEM	PANIPENEM	BETAMIPRON plasma	Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN
18.08 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=55 \| https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_372/_pdf/-char/en	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: PANIPENEM	PANIPENEM	BETAMIPRON plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
20.46 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=55 \| https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_372/_pdf/-char/en	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: PANIPENEM	PANIPENEM	BETAMIPRON plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
25.81 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=55 \| https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_372/_pdf/-char/en	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: PANIPENEM	PANIPENEM	BETAMIPRON plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
53 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=56 \| https://pubmed.ncbi.nlm.nih.gov/15729484/ \| https://www.jstage.jst.go.jp/article/jscpt1970/34/1/34_1_17S/_article/-char/en	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: PANIPENEM	PANIPENEM	BETAMIPRON plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
54.3 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=56 \| https://pubmed.ncbi.nlm.nih.gov/15729484/ \| https://www.jstage.jst.go.jp/article/jscpt1970/34/1/34_1_17S/_article/-char/en	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: PANIPENEM	PANIPENEM	BETAMIPRON plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
8.9 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=40 \| https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_242/_article/-char/en	250 mg single, intravenous dose: 250 mg route of administration: Intravenous experiment type: SINGLE co-administered: PANIPENEM	PANIPENEM	BETAMIPRON plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
19.7 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=40 \| https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_242/_article/-char/en	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: PANIPENEM	PANIPENEM	BETAMIPRON plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
31.29 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=40 \| https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_242/_article/-char/en	1000 mg single, intravenous dose: 1000 mg route of administration: Intravenous experiment type: SINGLE co-administered: PANIPENEM	PANIPENEM	BETAMIPRON plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
5.31 μg × h/mL EXPERIMENT https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_242/_article/-char/en	125 mg single, intravenous dose: 125 mg route of administration: Intravenous experiment type: SINGLE co-administered: PANIPENEM	PANIPENEM	BETAMIPRON plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
17.7 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=40 \| https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_265/_article/-char/en	500 mg 2 times / day multiple, intravenous dose: 500 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: PANIPENEM	PANIPENEM	BETAMIPRON plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
19.47 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=40 \| https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_265/_article/-char/en	500 mg 2 times / day multiple, intravenous dose: 500 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: PANIPENEM	PANIPENEM	BETAMIPRON plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
42.09 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=40 \| https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_265/_article/-char/en	1000 mg 2 times / day multiple, intravenous dose: 1000 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: PANIPENEM	PANIPENEM	BETAMIPRON plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
32.96 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=40 \| https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=51 \| https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_265/_article/-char/en	1000 mg 2 times / day multiple, intravenous dose: 1000 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: PANIPENEM	PANIPENEM	BETAMIPRON plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
20.4 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=55 \| https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_372/_pdf/-char/en	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: PANIPENEM	PANIPENEM	BETAMIPRON plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
37.61 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=55 \| https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_372/_pdf/-char/en	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: PANIPENEM	PANIPENEM	BETAMIPRON plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
194.67 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=55 \| https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_372/_pdf/-char/en	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: PANIPENEM	PANIPENEM	BETAMIPRON plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
630 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=56 \| https://pubmed.ncbi.nlm.nih.gov/15729484/ \| https://www.jstage.jst.go.jp/article/jscpt1970/34/1/34_1_17S/_article/-char/en	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: PANIPENEM	PANIPENEM	BETAMIPRON plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1898 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=56 \| https://pubmed.ncbi.nlm.nih.gov/15729484/ \| https://www.jstage.jst.go.jp/article/jscpt1970/34/1/34_1_17S/_article/-char/en	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: PANIPENEM	PANIPENEM	BETAMIPRON plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
0.65 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=40 \| https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_242/_article/-char/en	250 mg single, intravenous dose: 250 mg route of administration: Intravenous experiment type: SINGLE co-administered: PANIPENEM	PANIPENEM	BETAMIPRON plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.67 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=40 \| https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_242/_article/-char/en	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: PANIPENEM	PANIPENEM	BETAMIPRON plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.76 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=40 \| https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_242/_article/-char/en	1000 mg single, intravenous dose: 1000 mg route of administration: Intravenous experiment type: SINGLE co-administered: PANIPENEM	PANIPENEM	BETAMIPRON plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.65 h EXPERIMENT https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_242/_article/-char/en	125 mg single, intravenous dose: 125 mg route of administration: Intravenous experiment type: SINGLE co-administered: PANIPENEM	PANIPENEM	BETAMIPRON plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.81 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=40 \| https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_265/_article/-char/en	500 mg 2 times / day multiple, intravenous dose: 500 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: PANIPENEM	PANIPENEM	BETAMIPRON plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
0.71 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=40 \| https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_265/_article/-char/en	500 mg 2 times / day multiple, intravenous dose: 500 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: PANIPENEM	PANIPENEM	BETAMIPRON plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
0.78 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=40 \| https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_265/_article/-char/en	1000 mg 2 times / day multiple, intravenous dose: 1000 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: PANIPENEM	PANIPENEM	BETAMIPRON plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
0.79 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=40 \| https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=51 \| https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_265/_article/-char/en	1000 mg 2 times / day multiple, intravenous dose: 1000 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: PANIPENEM	PANIPENEM	BETAMIPRON plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
0.51 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=41 \| https://www.jstage.jst.go.jp/article/antibiotics1968b/45/2/45_208/_article/-char/en	10 mg/kg single, intravenous dose: 10 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: PANIPENEM	PANIPENEM	BETAMIPRON plasma	Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN
0.47 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=41 \| https://www.jstage.jst.go.jp/article/antibiotics1968b/45/2/45_208/_article/-char/en	20 mg/kg single, intravenous dose: 20 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: PANIPENEM	PANIPENEM	BETAMIPRON plasma	Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN
0.63 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=41 \| https://www.jstage.jst.go.jp/article/antibiotics1968b/45/2/45_208/_article/-char/en	30 mg/kg single, intravenous dose: 30 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: PANIPENEM	PANIPENEM	BETAMIPRON plasma	Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN
0.71 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=55 \| https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_372/_pdf/-char/en	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: PANIPENEM	PANIPENEM	BETAMIPRON plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1.31 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=55 \| https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_372/_pdf/-char/en	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: PANIPENEM	PANIPENEM	BETAMIPRON plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
5.77 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=55 \| https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_372/_pdf/-char/en	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: PANIPENEM	PANIPENEM	BETAMIPRON plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2.24 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=56 \| https://pubmed.ncbi.nlm.nih.gov/15729484/ \| https://www.jstage.jst.go.jp/article/jscpt1970/34/1/34_1_17S/_article/-char/en	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: PANIPENEM	PANIPENEM	BETAMIPRON plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
30.8 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=56 \| https://pubmed.ncbi.nlm.nih.gov/15729484/ \| https://www.jstage.jst.go.jp/article/jscpt1970/34/1/34_1_17S/_article/-char/en	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: PANIPENEM	PANIPENEM	BETAMIPRON plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
26.9% OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=40 \| https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=51 \| https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_265/_article/-char/en	1000 mg 2 times / day multiple, intravenous dose: 1000 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: PANIPENEM	PANIPENEM	BETAMIPRON plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
50.3% OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=56 \| https://pubmed.ncbi.nlm.nih.gov/15729484/ \| https://www.jstage.jst.go.jp/article/jscpt1970/34/1/34_1_17S/_article/-char/en	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: PANIPENEM	PANIPENEM	BETAMIPRON plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
0.5 g 1 times / 8 hours multiple, intravenous Dose: 0.5 g, 1 times / 8 hours Route: intravenous Route: multiple Dose: 0.5 g, 1 times / 8 hours Sources: https://pubmed.ncbi.nlm.nih.gov/18203711/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/18203711/	Sources: https://pubmed.ncbi.nlm.nih.gov/18203711/

PubMed

Title	Date	PubMed
Pharmacokinetics of 3-[125I]iodo-alpha-methyl-L-tyrosine, a tumor imaging agent, after probenecid loading in mice implanted with colon cancer DLD-1 cells.	2007-11	17998105
Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors.	2002-06	12023506
Characterization of organic anion transport inhibitors using cells stably expressing human organic anion transporters.	2001-05-11	11426832
Nephroprotective effect of betamipron on a new carbapenem, DA-1131, in rabbits.	1999-04	10211864
Betamipron reduces cisplatin nephrotoxicity in rodents without modifying its antileukemic activity in mice.	1997-05	9154659
Effects of betamipron on cisplatin nephrotoxicity and its pharmacokinetics in rats.	1997-04	9145215
Preventive effect of betamipron on nephrotoxicity and uptake of carbapenems in rabbit renal cortex.	1994-09	7861655

Patents

Sample Use Guides

In Vivo Use Guide

Intravenous drip infusion of either 10 mg/10 mg/kg or 20 mg/20 mg/kg of Panipenem/betamipron (PAPM/BP) for 30 minutes.

Route of Administration: Intravenous

In Vitro Use Guide

S2 hOAT2 cells were incubated in a medium containing 50 nM [3H]PGF2 at 37C for 2 min in the absence or presence of 1 mM betamipron, and the effect of the drug in PGF2 uptaked was studied. Inhibition of ES uptake by hOAT4 was measured at 500 uM of the drug.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:06:33 GMT 2025` Edited by `admin` on `Mon Mar 31 18:06:33 GMT 2025`
Record UNII	3W0M245736
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BETAMIPRON

Official Name

English

CS-443

Preferred Name

English

NSC-192714

Code

English

BETAMIPRON [JAN]

Common Name

English

Betamipron [WHO-DD]

Common Name

English

BETAMIPRON [MI]

Common Name

English

BETAMIPRON [MART.]

Common Name

English

N-BENZOYL-.BETA.-ALANINE

Systematic Name

English

betamipron [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C283